Precision Neuroscience raised $102M, closing its Series C funding
MobiHealthNews - 16-Dec-2024Company competes with Neuralink and Synchron to revolutionise AI-human integration
Join the club for FREE to access the whole archive and other member benefits.
Brain computer interface company
Synchron is a clinical-stage neurovascular bioelectronics medicine company. The company has pioneered an interventional neuromodulation platform and is developing the world’s first minimally-invasive motor neuroprosthesis, the Stentrode. The company is also developing endovascular neuromodulation solutions for the potential treatment of Parkinson’s disease, epilepsy, depression and hypertension, among other disorders.
July-2022: Bloomberg reported that Synchron implanted a device into the brain of an ALS patient at Mount Sinai West medical center on July 6,.
Visit website: https://www.synchronmed.com/
Details last updated 11-Nov-2020
Company competes with Neuralink and Synchron to revolutionise AI-human integration
ALS patient becomes first to use apple vision pro with BCI implant
Non-invasive neural device leads via blood vessel while Neuralink awaits human trials
Stentrode is an endovascular electrode array implanted through the blood vessels
Appears to be ahead in the race as already started human trials
Implantable brain computer interface received FDA approval for human trials in US